NVO · CUSIP 670100205
Novo Nordisk A/S
Reported by 4 of 79 curated managers in Q2 2026, in the holdings snapshot last exported 2026-10-26.
- Managers holding
- 4
- Average portfolio weight
- 0.8%
- Combined reported value
- $1.3B
- Research group
- 79
4 of the 79 superinvestors Shameless Cloning tracks reported Novo Nordisk A/S (NVO) in their Q2 2026 13F filings, worth $1.3B combined, at an average 0.8% of their portfolios. The largest positions by portfolio weight belong to Thomas Gayner (1.0%), Sarah Ketterer (0.9%), Lee Ainslie (0.7%).
Reporting managers
This is a historical 13F snapshot, not a live shareholder register. The count covers all matched managers; dashboard rankings use only those with at least 95% coverage. Reported value is measured at filing quarter-end, not at today's price.
| Manager / SEC filer | % of portfolio | Reported value |
|---|---|---|
| Thomas GaynerMarkel Group Inc. | 1.0% | $137.6M |
| Sarah KettererCAUSEWAY CAPITAL MANAGEMENT LLC | 0.9% | $80.4M |
| Lee AinslieMAVERICK CAPITAL LTD | 0.7% | $79.3M |
| Dodge & Cox FundsDodge & Cox | 0.5% | $977.8M |